SEP 07, 2016 12:00 PM PDT
Community Acquired Bacterial Pneumonia- a 2016 perspective.
Presented at the Microbiology & Immunology Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
2 2 87

Speakers:
  • SVP Medical Affairs, CEMPRA Inc
    Biography
      Glenn is a Senior Vice President at Cempra Inc in Chapel Hill, USA. He is trained in medical microbiology and infectious diseases and almost 30 of pharmaceutical industry experience in various areas including clinical research, commercialization, scientific communications including publication planning, strategic drug development, life cycle management and global launch programs. Glenn has been instrumental in the development of ciprofloxacin and moxifloxacin as well as other drugs in the Bayer portfolio for whom he worked for 15 years. He later worked for Optimer Pharmaceuticals as Senior Vice President of Medical Affairs and built a team to support the launch of fidaxomicin (Dificid) the first new antibiotic for C difficile in over 20 years. Glenn is a member of the Scientific Steering Committee for the GTCBio Annual Summit on Anti-infective Partnering as well as the Anaerobe Society. He is also past Chair of the ACCP Chest Infection Network and a member of the ACCP Executive Council of Networks. In 2009 Glenn was honored by the American College of Chest Physicians with the Alfred Soffer Award for contributions to the College. Glenn is on several journal Editorial Advisory Boards including the Lancet Infectious Disease and F1000.

    Abstract:

    Community acquired pneumonia affects over 5 million Americans and 6 million Europeans annually. Typically 5-10% will be admitted to hospital. It is a condition that more often affects the elderly with a commensurately higher mortality rate, which can be as high as 25%. Indeed over 50,000 deaths occur in the USA each year due to this infection. Diagnosis of pneumonia is almost exclusively clinical in terms of signs and symptoms although a positive chest X ray is vital.

    Approximately half of all pneumonia infections are caused by bacteria, the remainder are viral in origin. Streptococcus pneumoniae accounts for the majority of the bacterial cases. As with many other bacterial species the pneumococcus is becoming resistant to many of the commonly used antibiotics. As a result the US FDA has re-assigned the infection to be called Community Acquired Bacterial Pneumonia (CABP).

    Learned guidelines recommend either a macrolide or a doxycycline as the first choices for the low risk patient or a respiratory fluoroquinolone for those at higher risk or who have failed an initial course. Resistance to both first line agents is increasing in the USA   leading to a growing list of adverse consequences such as emergency room visits, hospitalization or re-admission to hospital. This presentation will review the current knowledge of the disease and the challenges of managing these patients.

    Learning Objective 1 : to appreciate the escalating burden of CABP in the USA

    Learning Objective 2 : to understand the impact antibiotic resistance can have in CABP

    Learning Objective 3 : to understand the current challenges in managing CABP
     


    Show Resources
    Loading Comments...